618 related articles for article (PubMed ID: 24177180)
21. Roscovitine suppresses CD4+ T cells and T cell-mediated experimental uveitis.
Zhang Z; Liu Q; Leskov KS; Wu X; Duan J; Zhang GL; Hall M; Rosenbaum JT
PLoS One; 2013; 8(11):e81154. PubMed ID: 24260551
[TBL] [Abstract][Full Text] [Related]
22. Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes.
Chen X; Li D; Cao Y; Gao J; Jin H; Shan H
Mol Pharm; 2019 Oct; 16(10):4252-4259. PubMed ID: 31454248
[TBL] [Abstract][Full Text] [Related]
23. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
Voo KS; Bover L; Harline ML; Vien LT; Facchinetti V; Arima K; Kwak LW; Liu YJ
J Immunol; 2013 Oct; 191(7):3641-50. PubMed ID: 24014877
[TBL] [Abstract][Full Text] [Related]
24. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
25. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
26. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
27. Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.
Polesso F; Weinberg AD; Moran AE
Cancer Immunol Res; 2019 Feb; 7(2):269-281. PubMed ID: 30563828
[TBL] [Abstract][Full Text] [Related]
28. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
29. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
Kitamura N; Murata S; Ueki T; Mekata E; Reilly RT; Jaffee EM; Tani T
Int J Cancer; 2009 Aug; 125(3):630-8. PubMed ID: 19455675
[TBL] [Abstract][Full Text] [Related]
30. OX40 costimulation turns off Foxp3+ Tregs.
Vu MD; Xiao X; Gao W; Degauque N; Chen M; Kroemer A; Killeen N; Ishii N; Li XC
Blood; 2007 Oct; 110(7):2501-10. PubMed ID: 17575071
[TBL] [Abstract][Full Text] [Related]
31. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.
Yokouchi H; Yamazaki K; Chamoto K; Kikuchi E; Shinagawa N; Oizumi S; Hommura F; Nishimura T; Nishimura M
Cancer Sci; 2008 Feb; 99(2):361-7. PubMed ID: 18201271
[TBL] [Abstract][Full Text] [Related]
32. Signaling through OX40 enhances antitumor immunity.
Jensen SM; Maston LD; Gough MJ; Ruby CE; Redmond WL; Crittenden M; Li Y; Puri S; Poehlein CH; Morris N; Kovacsovics-Bankowski M; Moudgil T; Twitty C; Walker EB; Hu HM; Urba WJ; Weinberg AD; Curti B; Fox BA
Semin Oncol; 2010 Oct; 37(5):524-32. PubMed ID: 21074068
[TBL] [Abstract][Full Text] [Related]
33. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.
Hirschhorn-Cymerman D; Rizzuto GA; Merghoub T; Cohen AD; Avogadri F; Lesokhin AM; Weinberg AD; Wolchok JD; Houghton AN
J Exp Med; 2009 May; 206(5):1103-16. PubMed ID: 19414558
[TBL] [Abstract][Full Text] [Related]
34. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
35. Bifunctional macromolecule activating both OX40 and interferon-α signaling displays potent therapeutic effects in mouse HBV and tumor models.
Mo S; Gu L; Xu W; Liu J; Ding D; Wang Z; Yang J; Kong L; Zhao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107099. PubMed ID: 33091819
[TBL] [Abstract][Full Text] [Related]
36. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
37. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
38. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
39. A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
Ryan JM; Mittal P; Menoret A; Svedova J; Wasser JS; Adler AJ; Vella AT
Cancer Immunol Immunother; 2018 Apr; 67(4):605-613. PubMed ID: 29327109
[TBL] [Abstract][Full Text] [Related]
40. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
